Grufity logoGrufity logo

Theravance Biopharma Inc Stock Research

TBPH

10.52USD+0.18(+1.74%)Market Closed

Market Summary

USD10.52+0.18
Market Closed
1.74%

TBPH Alerts

TBPH Stock Price

TBPH RSI Chart

TBPH Valuation

Market Cap

686.2M

Price/Earnings (Trailing)

0.79

Price/Sales (Trailing)

13.36

EV/EBITDA

-4.48

Price/Free Cashflow

-3.67

TBPH Price/Sales (Trailing)

TBPH Profitability

EBT Margin

-180.76%

Return on Equity

197.4%

Return on Assets

143.58%

Free Cashflow Yield

-27.25%

TBPH Fundamentals

TBPH Revenue

Revenue (TTM)

51.3M

Revenue Y/Y

-1.99%

Revenue Q/Q

17.65%

TBPH Earnings

Earnings (TTM)

872.1M

Earnings Y/Y

67.65%

Earnings Q/Q

-101.13%

Price Action

52 Week Range

7.5311.83
(Low)(High)

Last 7 days

-1.8%

Last 30 days

3.9%

Last 90 days

-6.9%

Trailing 12 Months

5.5%

TBPH Financial Health

Current Ratio

12.31

TBPH Investor Care

Buy Backs (1Y)

12.37%

Diluted EPS (TTM)

11.23

Peers (Alternatives to Theravance Biopharma)

View All Peers In Detail
NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
401.1B
94.9B
-3.25% -11.17%
22.36
4.23
1.25% -14.07%
302.8B
28.5B
2.15% 17.94%
48.48
10.61
0.79% 11.88%
272.8B
59.3B
-3.99% 33.34%
17.88
4.63
21.72% 11.27%
226.5B
100.3B
-4.70% -21.30%
7.22
2.26
23.43% 42.74%
143.9B
46.2B
-5.09% -4.47%
22.74
3.12
-0.49% -9.54%
MID-CAP
4.6B
4.5B
-7.51% -10.48%
-32.41
1.02
7.56% -104.06%
SMALL-CAP
2.1B
2.8M
167.83% 203.17%
-19.6
748.91
245.83% 12.43%
1.8B
666.8M
-7.47% -48.23%
112.99
2.7
23.14% -62.10%
1.6B
602.5M
-7.75% -62.41%
-2.78
2.67
18.18% -18.59%
923.6M
478.9M
-20.50% -75.95%
-0.29
1.93
-31.50% -634.70%
753.2M
213.9M
0.39% 48.49%
-20.6
3.52
105.41% 78.04%
738.3M
114.5M
-10.60% -51.38%
-4.38
6.45
27.90% 57.40%
686.2M
51.3M
3.85% 5.52%
0.79
13.36
-7.17% 537.32%
311.2M
55.3M
-19.49% -76.66%
-1.91
5.63
-29.00% -35.18%

Financials for Theravance Biopharma

Income Statement (Last 12 Months)
Description(%) Q/Q2022Q42022Q32022Q22022Q12021Q4
Revenue-0.6%51,346,00051,643,00052,386,00054,250,00055,311,000
Operating Expenses-20.8%148,361,000187,393,000227,549,000266,644,000313,095,000
  S&GA Expenses-9.2%67,073,00073,900,00078,922,00087,867,00099,296,000
  R&D Expenses-20.7%63,392,00079,917,000113,789,000149,311,000193,657,000
EBITDA-466.3%-86,446,00023,601,000-6,096,000-98,876,000-
EBITDA Margin-468.4%-1.680.46-0.12-1.82-
Earnings Before Taxes-121.2%-92,815,000-41,962,000-81,856,000-126,285,000-199,577,000
EBT Margin-122.5%-1.81-0.81-1.56-2.68-
Interest Expenses-90.3%6,369,00065,563,00066,154,00065,882,00046,889,000
Net Income2.5%872,132,000850,460,000-101,479,000-145,693,000-199,426,000
Net Income Margin3.1%16.9916.47-1.94-2.69-
Free Cahsflow-77.5%-186,991,000-105,370,000-128,679,000-164,062,000-
Balance Sheet
(In Millions)
* denotes actual numbers (not divided by Millions)
Description(%) Q/Q2022Q42022Q32022Q22022Q12021Q4
Assets-20.4%607763361355375
  Current Assets-30.9%353512155205250
    Cash Equivalents-28.6%29941987.0094.0090.00
  Net PPE-0.1%12.0012.0013.0013.0014.00
  Current Liabilities-79.8%29.0014233.0044.0059.00
Shareholder's Equity-8.1%442481-338--
  Retained Earnings-1.2%-853-843-1,760-1,751-1,726
  Additional Paid-In Capital-2.2%1,2961,3241,4101,4011,387
Shares Outstanding-3.2%65.0067.0076.0076.0074.00
Cashflow (Last 12 Months)
(In Millions)
Description(%) Q/Q2022Q42022Q32022Q22022Q12021Q4
Cashflow From Operations-77.5%-186-105-128-164-207
  Share Based Compensation-20.1%40.0050.0056.0061.0062.00
Cashflow From Investing2.5%1,1541,12614.0043.00124
Cashflow From Financing-4.9%-758-723-3.4410292.00
  Buy Backs-65.8%129376---

Risks for TBPH

What is the probability of a big loss on TBPH?

95.4%


Probability that Theravance Biopharma stock will be more than 20% underwater in next one year

91.9%


Probability that Theravance Biopharma stock will be more than 30% underwater in next one year.

57.7%


Probability that Theravance Biopharma stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does TBPH drawdown profile look like?

Y-axis is the maximum loss one would have experienced if Theravance Biopharma was unfortunately bought at previous high price.

Drawdowns

Returns for TBPH

Cumulative Returns on TBPH

-6.6%


7-Year Cumulative Returns

-16.6%


5-Year Cumulative Returns

-23.5%


3-Year Cumulative Returns

What are the long-term rolling returns for TBPH?

FIve years rolling returns for Theravance Biopharma.

Annualized Returns

Which funds bought or sold TBPH recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
2023-03-10
VICTORY CAPITAL MANAGEMENT INC
added
43.61
659,033
1,778,030
-%
2023-02-28
Voya Investment Management LLC
unchanged
-
28,148
291,148
-%
2023-02-21
MACQUARIE GROUP LTD
reduced
-2.47
166,000
2,343,000
-%
2023-02-15
ALLIANCEBERNSTEIN L.P.
unchanged
-
84,187
872,187
-%
2023-02-15
JANE STREET GROUP, LLC
reduced
-23.06
-286,152
1,639,850
-%
2023-02-15
Point72 Middle East FZE
new
-
40,942
40,942
-%
2023-02-14
MILLENNIUM MANAGEMENT LLC
added
3.83
982,000
7,579,000
-%
2023-02-14
Irenic Capital Management LP
new
-
19,084,500
19,084,500
9.15%
2023-02-14
Bank of New York Mellon Corp
added
2.98
290,107
2,374,110
-%
2023-02-14
Nuveen Asset Management, LLC
added
43.07
1,041,000
2,828,000
-%

1–10 of 40

Latest Funds Activity

Are funds buying TBPH calls or puts?
Calls
Puts
Are funds bullish or bearish(Calls - Puts)?
Net Call Options
No. of funds that own TBPH
No. of Funds

Theravance Biopharma News

MarketBeat

Theravance Biopharma, Inc. (NASDAQ:TBPH) Shares Purchased by ....

MarketBeat,
5 days ago

Seeking Alpha

Investopedia

Schedule 13G FIlings of Theravance Biopharma

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 14, 2023
madison avenue partners, lp
10.4%
7,012,226
SC 13G/A
Feb 14, 2023
orbimed advisors llc
0%
0
SC 13G/A
Feb 13, 2023
baupost group llc/ma
16.95%
11,419,226
SC 13G/A
Feb 09, 2023
vanguard group inc
8.25%
5,558,839
SC 13G/A
Jan 30, 2023
barclays plc
5.00%
3,371,298
SC 13G
Sep 20, 2022
gsk plc
0.0%
0
SC 13D/A
Jun 16, 2022
weiss asset management lp
8.09%
6,157,360
SC 13G
Apr 21, 2022
odre 2005 slu
5.5%
4,108,318
SC 13G
Feb 14, 2022
point72 asset management, l.p.
0.2%
145,100
SC 13G/A
Feb 14, 2022
madison avenue partners, lp
9.0%
6,648,025
SC 13G/A

TBPH Fair Value

Theravance Biopharma fair value in different scenarios

The table shows the Fair Value estimates for Theravance Biopharma for various scenarios. Disclaimer: These are just estimations from a model. None of the models are good at predicting the future. Please dont buy or sell stocks based on these outputs.
Fair ValueVery PessimisticPessimisticBase CaseOptimisticVery Optimistic
Very Low Inflation

0.83

-92.11%

1.14

-89.16%

2.65

-74.81%

5.86

-44.30%

7.19

-31.65%
Current Inflation

0.78

-92.59%

1.05

-90.02%

2.39

-77.28%

5.20

-50.57%

6.34

-39.73%
Very High Inflation

0.71

-93.25%

0.95

-90.97%

2.09

-80.13%

4.41

-58.08%

5.33

-49.33%

Historical Theravance Biopharma Fair Value Estimates


Very Pessimistic Case
Pessimistic Case
Fair Value
Optimistic Case
Very Optimistic Case
Closing Stock Price

Recent SEC filings of Theravance Biopharma

View All Filings
Date Filed Form Type Document
Mar 17, 2023
PRE 14A
PRE 14A
Mar 16, 2023
4
Insider Trading
Mar 13, 2023
4
Insider Trading
Mar 13, 2023
8-K
Current Report
Mar 08, 2023
4
Insider Trading
Mar 03, 2023
4
Insider Trading
Mar 03, 2023
4
Insider Trading
Mar 03, 2023
4
Insider Trading
Mar 03, 2023
4
Insider Trading
Mar 03, 2023
4
Insider Trading

Latest Insider Trading transactions for TBPH

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
2023-03-14
GRAHAM RICHARD A
sold
-23,973
10.32
-2,323
svp, research & development
2023-03-09
Farnum Rhonda
sold
-40,800
10.2
-4,000
svp, comm & medical affairs
2023-03-06
GRAHAM RICHARD A
sold
-23,346
10.05
-2,323
svp, research & development
2023-03-01
Sawaf Aziz
acquired
-
-
80,000
svp & chief financial officer
2023-03-01
Grimaud Brett A.
acquired
-
-
75,000
svp, gen counsel and secretary
2023-03-01
GRAHAM RICHARD A
acquired
-
-
75,000
svp, research & development
2023-03-01
Farnum Rhonda
acquired
-
-
75,000
svp, comm & medical affairs
2023-03-01
Winningham Rick E
acquired
-
-
330,000
chief executive officer
2023-02-26
GRAY SUSANNAH
acquired
-
-
11,819
-
2023-02-20
Grimaud Brett A.
sold (taxes)
-106,467
10.44
-10,198
svp, gen counsel and secretary

1–10 of 50

Rick E. Winningham
160
Theravance Biopharma, Inc., a biopharmaceutical company, discovers, develops, and commercializes respiratory medicines in the United States, Europe, and Asia. The company offers YUPELRI, a once-daily, nebulized long-acting muscarinic antagonist used for the treatment of chronic obstructive pulmonary disease (COPD). Its product portfolio also include Izencitinib, a gut-selective pan-janus kinase (JAK) inhibitor that is in Phase IIb/III clinical trials for the treatment of rheumatoid arthritis, myelofibrosis, and ulcerative colitis, as well as for a range of inflammatory intestinal diseases, including ulcerative colitis and Crohn's disease. In addition, the company's product portfolio comprise Ampreloxetine, an investigational norepinephrine reuptake inhibitor that has completed Phase III study for neurogenic orthostatic hypotension; Nezulcitinib, a lung-selective, nebulized JAK inhibitor, which is in Phase II clinical development for the potential treatment of hospitalized patients with acute lung injury caused by COVID-19; Inhaled ALK5i, a potential inhaled anti-fibrotic agent that is in Phase I for the treatment of idiopathic pulmonary fibrosis; and TD-5202, an investigational, orally administered, gut-selective, irreversible JAK3 inhibitor that is in Phase I clinical study for treatment of inflammatory intestinal diseases. Further, it offers TRELEGY for the treatment of COPD and asthma; Velusetrag, an oral and investigational medicine for gastrointestinal motility disorders; and Selective 5-HT4 Agonist for treatment of gastrointestinal motility disorders. It has a licensing and collaboration agreements with Pfizer Inc., Viatris Inc., Janssen Biotech, Inc., Alfasigma S.p.A, and Takeda Pharmaceutical Company Limited. Theravance Biopharma, Inc. was incorporated in 2013 and is based in George Town, the Cayman Islands.

TBPH Income Statement

2022-12-31
CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
shares in Thousands, $ in Thousands
12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Revenue:   
Total revenue$ 51,346$ 55,311$ 71,857
Expenses:   
Research and development (1)63,392193,657260,953
Selling, general and administrative (1)67,07399,296108,531
Restructuring and related expenses (1)12,83820,142 
Total expenses143,303313,095369,484
Loss from operations(91,957)(257,784)(297,627)
Interest expense(6,369)(8,547)(8,547)
Loss on extinguishment of debt(3,034)  
Interest income and other income, net8,5451,1092,831
Loss from continuing operations before income taxes(92,815)(265,222)(303,343)
Provision for income tax (expense) benefit(9)1518,520
Net loss from continuing operations(92,824)(265,071)(294,823)
Income from discontinued operations before income taxes1,143,93065,64516,806
Provision for income tax expense(178,974)  
Net income from discontinued operations964,95665,64516,806
Net income (loss)$ 872,132$ (199,426)$ (278,017)
Net income (loss) per share:   
Continuing operations - basic$ (1.26)$ (3.82)$ (4.73)
Continuing operations - diluted(1.26)(3.82)(4.73)
Discontinued operations - basic13.110.950.27
Discontinued operations - diluted13.110.950.27
Net income (loss) - basis11.85(2.87)(4.46)
Net income (loss) - diluted$ 11.85$ (2.87)$ (4.46)
Shares used to compute basis and diluted net income (loss) per share73,59169,46162,345
Shares used to compute basis and diluted net income (loss) per share73,59169,46162,345
Total share-based compensation expense$ 39,734$ 62,061$ 62,976
Research and development   
Expenses:   
Restructuring and related expenses (1)5,90010,600 
Net income (loss) per share:   
Total share-based compensation expense12,88825,63431,294
Selling, general and administrative   
Expenses:   
Restructuring and related expenses (1)6,9009,500 
Net income (loss) per share:   
Total share-based compensation expense19,84828,06531,682
Restructuring and related expenses   
Net income (loss) per share:   
Total share-based compensation expense6,9988,362 
Viatris collaboration agreement   
Revenue:   
Total revenue48,62443,84843,893
Viatris royalties (Non-US)   
Revenue:   
Total revenue30  
Collaboration revenue   
Revenue:   
Total revenue192$ 11,46326,464
Licensing revenue   
Revenue:   
Total revenue$ 2,500 $ 1,500

TBPH Balance Sheet

2022-12-31
CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Thousands
Dec. 31, 2022
Dec. 31, 2021
Current assets:  
Cash and cash equivalents$ 298,172$ 89,959
Short-term marketable securities29,31283,506
Receivables from collaborative arrangements16,78514,065
Prepaid clinical and development services1,51310,245
Other prepaid and current assets7,6828,561
Amounts due from TRC, LLC (Discontinued operations) 43,534
Total current assets353,464249,870
Property and equipment, net11,87513,657
Operating lease assets40,12639,690
Future contingent milestone and royalty assets194,200 
Restricted cash836837
Other assets6,8993,228
Equity in net assets of TRC, LLC (Discontinued operations) 67,537
Total assets607,400374,819
Current liabilities:  
Accounts payable1,5543,098
Accrued personnel-related expenses10,31412,796
Accrued clinical and development expenses4,93217,010
Accrued general and administrative expenses4,0202,898
Operating lease liabilities6,753503
Deferred revenue2498
Other accrued liabilities1,1181,304
Accrued interest payable 1,246
Current portion of non-recourse notes due 2035, net (Discontinued operations) 16,940
Accrued interest payable (Discontinued operations) 2,694
Total current liabilities28,71558,587
Long-term operating lease liabilities45,40752,681
Future royalty payment contingency25,438 
Long-term deferred revenue192310
Unrecognized tax benefits64,191240
Other long-term liabilities1,6572,180
Convertible senior notes due 2023, net 228,035
Non-recourse notes due 2035, net 371,359
Commitments and contingencies
Shareholders' Equity (Deficit)  
Preferred shares, $0.00001 par value: 230 shares authorized, no shares issued or outstanding
Ordinary shares, $0.00001 par value: 200,000 shares authorized; [65,227] and 74,435 shares issued and outstanding at December 31, 2022 and December 31, 2021, respectively11
Additional paid-in capital1,295,7251,387,469
Accumulated other comprehensive loss(15) 
Accumulated deficit(853,911)(1,726,043)
Total shareholders' equity (deficit)441,800(338,573)
Total liabilities and shareholders' equity (deficit)$ 607,400$ 374,819